Sign in
Taking peoplePhase 4

Metformin in Post Chronic Pancreatitis Diabetes Mellitus

Key facts

Who runs it
Changhai Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
58 people, planned
Started
28 Apr 2025
Planned end
31 Jan 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Metformin
  • Placebo
Record updated
21 May 2025

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Aged 18-65 years, any sex
  • Patients diagnosed with chronic pancreatitis
  • Diagnose diabetes at least 3 months after chronic pancreatitis diagnosis
  • Never used any diabetes drug/glucose-lowering medication or had discontinued any glucose-lowering medications for at least 8 weeks prior to screening
  • HbA1c criteria: 7.5%~9.0%
  • BMI >18.5
  • Provision of signed informed consent

Who cannot take part

  • Acute episodes of chronic pancreatitis at enrollment or within 3 months prior to enrollment
  • Previous organ transplantation
  • Treatment with oral or systemic glucocorticoids within 3 months prior to enrollment or plan to use during the study (inhaled steroids are permitted)
  • Type 1 diabetes or secondary diabetes not caused by chronic pancreatitis (e.g. diabetes due to monogenic defects, cystic fibrosis, medications, autoimmune diseases, stress, or other factors)
  • Contraindications or history of intolerance or allergy to metformin
  • History of congestive heart failure (NYHA class 3 or greater), unstable angina, or other severe cardiovascular diseases
  • History of cancer (except non-melanoma skin cancer) within 5 years prior to screening
  • History of partial or total pancreatectomy
  • History of or planning bariatric surgery
  • Sever psychiatric disorders or health conditions deemed unsuitable for clinical research participation
  • Any other condition considered by the investigator to be inappropriate for participation in the trial
  • History of hemolytic anemia, chronic transfusion requirements, or other conditions rendering HbA1c results unreliable
  • Other conditions requiring glucose-lowering medications, such as polycystic ovary syndrome
  • Fasting blood glucose >11.1 mmol/L during screening, requiring immediate treatment as judged by the physician
  • Fasting C-peptide <0.3 nmol/L
  • Pregnancy or plans for pregnancy during the course of the study

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to evaluate the efficacy and safety of metformin in treating patients with post chronic pancreatitis diabetes mellitus (PPDM-C). The main questions it aims to answer are:

Read full original descriptionShow less

* What is the efficacy of metformin in glycemic control in patients with PPDM-C? * What is the incidence of adverse effects associated with metformin in patients with PPDM-C?

Participants will be randomly assigned to receive either metformin or a placebo to see if metformin provides significant glycemic control and to assess the safety profile of the treatment.

The 2 groups in the trial

  • MetforminTreatment being tested

    Participants are administered metformin with an initial dose of 500 mg/day, which was incrementally increased by 500 mg/day each week until the maximum tolerated dose. The maximum dose of metformin is set at 2000 mg/day. After 2 weeks of administration, participants will undergo safety assessments, including complete blood count, urinalysis, liver function tests, and renal function tests. After attainment to a stable dose of metformin, participants will undergo follow-up assessments at 4 weeks, 8 weeks, and 12 weeks. The final evaluation of outcome measures will be completed at the 12-week follow-up.

  • PlaceboPlacebo, for comparison

    Participants are administered a placebo, starting with one tablet per day, followed by an incremental increase of one tablet per week. In the absence of adverse reactions, the dosage is escalated up to a maximum of four tablets per day. After 2 weeks of administration, participants will undergo safety assessments, including complete blood count, urinalysis, liver function tests, and renal function tests. After attainment to a stable dose, participants will undergo follow-up assessments at 4 weeks, 8 weeks, and 12 weeks. The final evaluation of outcome measures will be completed at the 12-week follow-up.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Metformin in Post Chronic Pancreatitis Diabetes Mellitus: a Double-blind, Randomized, Placebo-controlled Trial
Criteria questions
Built from NCT06937294, who can take part
Record updated
21 May 2025